Vol. 117, n. 2 (Supplement): 64, 2012

Myogenic potential of human peripheral blood cells

<u>Rosa Di Liddo</u>¹, Thomas Bertalot¹, Silvia Barbon¹, Marco Gasparella², Senthil Kumar Rajendran¹, Pier Paolo Parnigotto¹ and Maria Teresa Conconi¹

¹Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
²Department of Women's and Children's Health, University of Padua, Padua, Italy

In the search of cell types useful to treat skeletal muscle disfunctions, this work dealt with isolation, characterization and evaluation of myogenic potential of adherent fibroblastic cells from human peripheral blood (hPBCs).

hPBCs were obtained by Ficoll density gradient separation and characterized by SEM, RT-PCR, FACS, Western blot, and immunocytochemistry. Myogenic induction was carried out using a differentiation medium containing insulin-like growth factor-1 and ascorbic acid.

hPBCs showed a mesenchymal stem cell profile being CD73+/CD90+/CD105+ and possessed a doubling population time of 48 hours over 31 passages. After induction with myogenic factors, these cells formed multi-nucleated elements and expressed myogenic markers. At one week from injection in the rat tiibialis anterior muscle, previously damaged with bupivacaine [1], transplanted cells were detectable in the muscle and differentiated into skeletal muscle cells, as demonstrated by immunofluorescence.

Taken together, our results show that hPBCs possess myogenic potential both in vitro and in vivo and may represent a promising tool for the treatment of skeletal muscle disorders.

References

 Conconi et al. (2006) CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. Int J Mol Med 18(6): 1089-1096.

Keywords: Peripheral blood, mesenchymal stem cells, skeletal muscle, regenerative medicine.